- CEO
- Ghanshyam Arjanbhai Patel
- Full Time Employees
- 260
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 314, Shangrilla Arcade, Shyamal Cross Road, Anandnagar Road, Satellite Ahmedabad GU India 380015
- IPO Date
- Dec 15, 2023
- Business
- Accent Microcell Ltd. (NSE:ACCENTMIC) manufactures, sells, and trades cellulose-based excipients primarily for the pharmaceutical industry in India and internationally. The company offers microcrystalline cellulose (including spray-dried and spin flash-dried grades), powdered cellulose, microcrystalline cellulose spheres, silicified microcrystalline cellulose, crosscarmellose sodium, magnesium stearate, and microcrystalline cellulose with carboxymethyl cellulose; it sells these products under the Accel, Vincel, Acrocell, and Maccel brands. Accent Microcell also serves diverse sectors including nutraceuticals, food, bakery, dairy, meat and seafood, extrusion, cosmeceuticals and personal care, welding, paints, cement, construction, ceramics, rubber, enzymes, textile, leather, paper, boards, welding electrodes, filtration, and plastics, with exports to approximately 36 countries. In addition, the company provides supply chain management, on-time material delivery, customer assistance, and quality commitment services. Founded in 2001 and headquartered in Ahmedabad, Gujarat, India, Accent Microcell operates manufacturing facilities at Pirana (Unit-I) and Dahej SEZ (Unit-II). Recent developments include its public listing on the National Stock Exchange (NSE) in 2023, robust financial performance with revenue of INR 278 crore and profit of INR 34.7 crore for the trailing twelve months as of late 2025, and board approval of unaudited half-year results for the period ended September 30, 2025, alongside statements on IPO proceeds utilization in October 2025. The company has maintained strong profit growth at a 51.2% CAGR over the last five years, reduced debt levels to near debt-free status, and recommended a final dividend of INR 1.00 per equity share for fiscal year 2025.